
Algen Bio is revolutionizing therapeutic drug discovery by leveraging advanced CRISPR gene-modulation and AI. Their proprietary AlgenCRISPR system enables precise gene modulation, powering the AlgenBrain platform to industrialize single-cell, combinatorial gene modulation. This platform utilizes deep learning models trained on vast datasets of gene expression changes to predict RNA signaling networks and uncover disease-driving pathways. Originating from the lab of CRISPR pioneer Jennifer Doudna, Algen Bio aims to accelerate the identification of impactful therapeutic endpoints for complex diseases.

Algen Bio is revolutionizing therapeutic drug discovery by leveraging advanced CRISPR gene-modulation and AI. Their proprietary AlgenCRISPR system enables precise gene modulation, powering the AlgenBrain platform to industrialize single-cell, combinatorial gene modulation. This platform utilizes deep learning models trained on vast datasets of gene expression changes to predict RNA signaling networks and uncover disease-driving pathways. Originating from the lab of CRISPR pioneer Jennifer Doudna, Algen Bio aims to accelerate the identification of impactful therapeutic endpoints for complex diseases.
Sector: Biotechnology — therapeutic discovery
Core tech: Proprietary AlgenCRISPR gene-modulation + AlgenBrain AI models
Scientific origin: Research originating from Jennifer Doudna's lab (UC Berkeley)
Headquarters: San Francisco, California, United States
Employees (approx.): 14
| Company |
|---|
Therapeutic target discovery and decoding functional gene networks in complex diseases.
2018
Biotechnology
Crunchbase lists two funding rounds and a Seed as the most recent; company-reported investors include Viking, Cota Capital, Draper, Illumina Accelerator, Rebel Fund, Sequoia Capital, Y Combinator and others.
“Company lists strategic investors including Viking, Cota Capital, Draper, Illumina Accelerator, Y Combinator and Rebel; Crunchbase reports additional investors including Sequoia Capital and Viking.”